NewsHealth / October 27, 2020

Eli Lilly Halts Trial For COVID-19 Treatment On Hospitalized Patients

Article origination IPBS-RJC
Eli Lilly Corporate Headquarters in Indianapolis.  - Lauren Chapman/IPB News

Eli Lilly Corporate Headquarters in Indianapolis.

Lauren Chapman/IPB News

Indianapolis-based Eli Lilly has ended testing its COVID-19 antibody therapy on hospitalized patients. Earlier this month, Eli Lilly temporarily suspended the trial for the drug due to a safety concern. 

In a news release, the company said recent data showed there wasn’t a significant difference in outcomes for COVID-19 patients in advanced stages who received the treatment compared to those who did not.

The trial was evaluating recovery chances for severe cases when the drug was administered in combination with an antiviral medication that was recently approved by the Food and Drug Administration.

READ MORE: Study Pauses Are More Common, Essential To Clinical Trials

This study was being done in partnership with the National Institute of Allergy and Infectious Diseases and that was the only one testing bamlanivimab in COVID-19 hospitalized patients.

The pharmaceutical company will continue trials of the drug in other settings including nursing homes.

Contact reporter Samantha at shorton@wfyi.org or follow her on Twitter at @SamHorton5.

At WFYI, our goal is to cover stories that matter to you. Our reporting is rooted in facts. It considers all perspectives and is available to everyone. We don't have paywalls, but we do need support. So if unbiased, trusted journalism is important to you, please join us. Donate now.

 

 

Related News

Indiana Nears Topping Monthly High For COVID-19 Deaths
Updates On COVID-19 In Indiana: 103 Deaths, 5,702 Cases, Added To State's Totals
Indiana Adds More Than 100,000 New COVID-19 Cases In 17 Days